TherapeuticsMD (TXMD) Competitors $1.06 0.00 (0.00%) As of 11:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TXMD vs. LTRN, PDSB, AADI, MDCX, NBRV, SCYX, TELO, ESLA, IPSC, and RNXTShould you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Lantern Pharma (LTRN), PDS Biotechnology (PDSB), Aadi Bioscience (AADI), Medicus Pharma (MDCX), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Telomir Pharmaceuticals (TELO), Estrella Immunopharma (ESLA), Century Therapeutics (IPSC), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry. TherapeuticsMD vs. Its Competitors Lantern Pharma PDS Biotechnology Aadi Bioscience Medicus Pharma Nabriva Therapeutics SCYNEXIS Telomir Pharmaceuticals Estrella Immunopharma Century Therapeutics RenovoRx TherapeuticsMD (NASDAQ:TXMD) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings. Which has more volatility and risk, TXMD or LTRN? TherapeuticsMD has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Is TXMD or LTRN more profitable? Lantern Pharma has a net margin of 0.00% compared to TherapeuticsMD's net margin of -17.94%. TherapeuticsMD's return on equity of -2.01% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets TherapeuticsMD-17.94% -2.01% -1.40% Lantern Pharma N/A -99.89%-81.58% Do institutionals and insiders believe in TXMD or LTRN? 30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 2.3% of TherapeuticsMD shares are held by company insiders. Comparatively, 8.5% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher earnings and valuation, TXMD or LTRN? TherapeuticsMD has higher revenue and earnings than Lantern Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTherapeuticsMD$1.76M6.97-$2.18MN/AN/ALantern PharmaN/AN/A-$20.78M-$1.78-2.59 Do analysts rate TXMD or LTRN? Lantern Pharma has a consensus target price of $25.00, indicating a potential upside of 442.42%. Given Lantern Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Lantern Pharma is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor TXMD or LTRN? In the previous week, TherapeuticsMD and TherapeuticsMD both had 1 articles in the media. TherapeuticsMD's average media sentiment score of 0.00 equaled Lantern Pharma'saverage media sentiment score. Company Overall Sentiment TherapeuticsMD Neutral Lantern Pharma Neutral SummaryLantern Pharma beats TherapeuticsMD on 6 of the 11 factors compared between the two stocks. Get TherapeuticsMD News Delivered to You Automatically Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXMD vs. The Competition Export to ExcelMetricTherapeuticsMDMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.26M$2.65B$9.08B$10.58BDividend YieldN/A56.71%5.69%4.71%P/E RatioN/A23.4386.1627.45Price / Sales6.97583.66539.92202.26Price / CashN/A173.2337.9261.55Price / Book0.455.5913.056.77Net Income-$2.18M$32.78M$3.30B$275.88M7 Day PerformanceN/A5.84%4.55%2.63%1 Month Performance-1.85%13.22%9.73%9.10%1 Year Performance-32.91%2.13%85.10%35.69% TherapeuticsMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXMDTherapeuticsMD0.1899 of 5 stars$1.06flatN/A-34.6%$12.26M$1.76M0.00420Analyst ForecastLTRNLantern Pharma2.0246 of 5 stars$4.54+2.0%$25.00+450.7%+24.4%$48.11MN/A-2.5520Analyst ForecastPDSBPDS Biotechnology1.6696 of 5 stars$1.01-1.0%$10.00+890.1%-71.9%$47.97MN/A-1.1020Analyst ForecastAADIAadi BioscienceN/A$1.94+2.6%N/A+13.8%$47.91M$25.07M-0.8540MDCXMedicus Pharma2.6529 of 5 stars$2.51-4.6%$23.50+836.3%N/A$46.86MN/A-1.87N/AAnalyst ForecastNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070SCYXSCYNEXIS0.4707 of 5 stars$1.05-2.3%N/A-47.9%$45.07M$3.26M-2.6260TELOTelomir Pharmaceuticals2.8014 of 5 stars$1.34-3.6%$15.00+1,019.4%-68.3%$44.87MN/A-2.481News CoverageAnalyst ForecastGap UpESLAEstrella Immunopharma1.9951 of 5 stars$1.19-0.8%$16.00+1,244.5%+40.3%$44.48MN/A-4.58N/ANews CoverageAnalyst ForecastIPSCCentury Therapeutics2.4606 of 5 stars$0.50-1.9%$3.75+650.6%-60.0%$43.98M$6.59M-1.72170Analyst ForecastGap UpRNXTRenovoRx1.7502 of 5 stars$1.18flat$7.50+535.6%+21.1%$43.24M$662K-3.116Analyst Forecast Related Companies and Tools Related Companies Lantern Pharma Alternatives PDS Biotechnology Alternatives Aadi Bioscience Alternatives Medicus Pharma Alternatives Nabriva Therapeutics Alternatives SCYNEXIS Alternatives Telomir Pharmaceuticals Alternatives Estrella Immunopharma Alternatives Century Therapeutics Alternatives RenovoRx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXMD) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
